This study aims to explore the efficacy and safety of Anlotinib plus PD-1 antibody in Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
This study aims to explore the efficacy and safety of Anlotinib plus PD-1 antibody in Standard Chemotherapy Failure Advanced Non-small Cell Lung Cancer (Athena study）